PHAT Phathom Pharmaceuticals, Inc.
Nasdaq · SEC CIK 1783183 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $7,079 1 sales by 1 insiders
- Filings on record
- 140 since 2021-07-06, latest 2026-09-08 16:30
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Breedlove Robert Charles | Principal Accounting Off | — | $7,079 |
| Narula Sanjeev | Chief Financial, Bus. Off | — | — |
| Parikh Asit | Dir | — | — |
| Stenhouse Mark | Dir | — | — |
| Basta Steven L | Pres, CEO, Dir | — | — |
| Schroeder Theodore R | Dir | — | — |
| Topper James N | Dir, 10% | — | — |
| Cook Anne Marie | Chief Legal Off, Corp. Sec | — | — |
| KARBE FRANK | Dir | — | — |
| COLA MICHAEL F | Dir | — | — |
Transactions 139
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-23 | 2023-05-22 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $12.87 | -2,110 | 70.5K | -3% | -$27.2K | |
| 2023-04-11 | 2023-04-10 | PHAT | Parikh Asit | Dir | P - Purchase | $7.55 | +1,000 | 23.5K | +4% | +$7,550 | |
| 2023-04-11 | 2023-04-11 | PHAT | Nabulsi Azmi | COO | P - Purchase | $8.26 | +10.0K | 99.6K | +11% | +$82.6K | |
| 2023-04-07 | 2023-04-06 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | P - Purchase | $7.82 | +12.9K | 188.3K | +7% | +$101.0K | |
| 2023-04-07 | 2023-04-06 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $7.27 | -3,439 | 72.6K | -5% | -$25.0K | |
| 2023-03-03 | 2023-03-01 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | S - Sale | $8.54 | -1,436 | 175.4K | -0.8% | -$12.3K | |
| 2023-03-03 | 2023-03-01 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $8.53 | -2,032 | 76.0K | -3% | -$17.3K | |
| 2023-02-14 | 2023-02-13 | PHAT | Parikh Asit | Dir | P - Purchase | $7.73 | +5,000 | 22.5K | +29% | +$38.6K | |
| D | 2023-01-20 | 2023-01-19 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +45.0K | 89.6K | +101% | $0 |
| D | 2023-01-20 | 2023-01-19 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +97.5K | 182.6K | +115% | $0 |
| D | 2023-01-20 | 2023-01-20 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | S - Sale | $8.20 | -5,821 | 176.8K | -3% | -$47.7K |
| D | 2023-01-20 | 2023-01-19 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +33.0K | 78.0K | +73% | $0 |
| 2023-01-12 | 2023-01-12 | PHAT | Parikh Asit | Dir | P - Purchase | $7.00 | +5,000 | 17.5K | +40% | +$35.0K | |
| 2022-11-23 | 2022-11-21 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | S - Sale | $9.60 | -1,526 | 83.7K | -2% | -$14.6K | |
| 2022-11-23 | 2022-11-21 | PHAT | Henderson Molly | CFO, CBO | S - Sale | $9.60 | -2,159 | 43.3K | -5% | -$20.7K | |
| 2022-09-02 | 2022-09-01 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +7,500 | 85.2K | +10% | $0 | |
| 2022-09-02 | 2022-09-01 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +7,500 | 42.0K | +22% | $0 | |
| 2022-09-02 | 2022-09-01 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +7,500 | 45.5K | +20% | $0 | |
| 2022-05-20 | 2022-05-19 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +12.0K | 33.4K | +56% | $0 | |
| 2022-05-20 | 2022-05-19 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +12.0K | 38.0K | +46% | $0 | |
| 2022-05-20 | 2022-05-19 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +12.0K | 76.6K | +19% | $0 | |
| 2022-05-16 | 2022-05-13 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | P - Purchase | $7.41 | +20.5K | 64.6K | +46% | +$151.9K | |
| 2022-05-16 | 2022-05-13 | PHAT | Henderson Molly | CFO, CBO | P - Purchase | — | +6,000 | 26.0K | +30% | — | |
| I | 2022-05-16 | 2022-05-16 | PHAT | Nabulsi Azmi | COO | P - Purchase | $8.16 | +20.0K | 785.7K | +3% | +$163.2K |
| 2022-05-16 | 2022-05-12 | PHAT | Parikh Asit | Dir | P - Purchase | $8.00 | +12.5K | 12.5K | New | +$100.0K | |
| D | 2022-04-06 | 2022-04-05 | PHAT | Henderson Molly | CFO, CBO | A - Grant | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2022-03-16 | 2022-03-14 | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | X - OptEx | $0.00 | +7.36M | 7.46M | +7,359% | $0 |
| D | 2022-03-16 | 2022-03-14 | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | S - Sale+OE | $19.00 | -18 | 7.46M | -0.0% | -$342 |
| 2022-02-18 | 2019-10-29 | PHAT | COLA MICHAEL F | Dir | P - Purchase | $19.00 | +9,798 | 9,798 | New | +$186.2K | |
| D | 2022-01-21 | 2022-01-19 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +41.2K | 44.1K | +1,450% | $0 |
| D | 2022-01-21 | 2022-01-19 | PHAT | Guzzo Anthony J. | VP, CAO | A - Grant | $0.00 | +6,000 | 8,399 | +250% | $0 |
| D | 2022-01-21 | 2022-01-19 | PHAT | Nabulsi Azmi | COO | A - Grant | $0.00 | +19.5K | 21.4K | +1,038% | $0 |
| DM | 2021-11-08 | 2021-11-04 | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | S - Sale+OE | $20.85 | -1.00M | 100.0K | -91% | -$20.85M |
| D | 2021-11-08 | 2021-11-04 | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | X - OptEx | $0.00 | +228.7K | 1.10M | +26% | $0 |
| MI | 2021-10-08 | 2021-10-07+ | PHAT | Socks David A | Dir | S - Sale | $32.57 | -18.0K | 1.21M | -1% | -$586.3K |
| MI | 2021-09-23 | 2021-09-21+ | PHAT | Socks David A | Dir | S - Sale | $32.63 | -18.0K | 1.23M | -1% | -$587.4K |
| MI | 2021-08-18 | 2021-08-16 | PHAT | Socks David A | Dir | S - Sale | $31.25 | -18.0K | 1.26M | -1% | -$562.5K |
| 2021-07-09 | 2021-07-07 | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | S - Sale | $35.05 | -2,609 | 871.3K | -0.3% | -$91.4K | |
| M | 2021-07-06 | 2021-07-01+ | PHAT | TAKEDA PHARMACEUTICAL CO LTD | 10% | S - Sale | $35.16 | -8,326 | 874.0K | -0.9% | -$292.7K |
Purchase Sale Sale after option exercise All abbreviations